Navigation Links
Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
Date:12/6/2007

mast cells by blocking the activation of syk kinase.

R343 will be delivered via the inhaled route using a dry powder inhaler and will initially be tested in healthy volunteers to evaluate its safety, dosing and pharmacodynamics. R343 is not orally bio-available and is a different molecule from R788. R788 is an orally bio-available syk kinase inhibitor in development by Rigel for various autoimmune and hematological indications and is not part of this collaboration.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the clinical development of R343 and the potential efficacy of Rigel's product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "may," "expects," "goal" and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations. Forward-looking statements involve risks and uncertainties. There are a number of i
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... schools across the country, teachers are directed to send students ... have a vision issue.  This could be due to the ... the blackboard, poor performance in class or disruptive behavior. The ... difficult and that student could end up in the principal,s ...
... largest professional network for physicians, announced today ... power their medical expert searches. These firms are the ... million in honoraria to physicians last year. Using Doximity,s ... of over 30,000 physician experts. For physicians,  ...
Cached Medicine Technology:Disruptive Students May Not Be Able to See Their Problem 2Disruptive Students May Not Be Able to See Their Problem 3Disruptive Students May Not Be Able to See Their Problem 4Doximity Launches ExpertFinder to Match Clinical Need with Clinical Experts 2
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special ... new range of gorgeous Quinceanera dresses . ... for elegant Quinceanera outfits is huge. Therefore, 2014QuinceaneraDresses.com ... the company’s newly released dresses are made according ... elegant and vivid. , It is worthy ...
(Date:7/13/2014)... imaging device developed at Cedars-Sinai can provide early ... brain and are a classic sign of Alzheimer,s ... a clinical trial in Australia. , The researchers ... oral presentation at the Alzheimer,s Association International Conference ... by conference organizers to participate in a "breaking ...
(Date:7/13/2014)... 2014 Celebrity fitness trainer and former ... promotional partnership with Aqua Health Labs for their flagship ... supplement . The collaboration was recently announced live on ... trainer , actor, model, and a two time World ... celebrities, he has prepared stars including Demi Moore, Hilary ...
(Date:7/13/2014)... Seattle, Wa (PRWEB) July 13, 2014 ... updated by Vkool.com, this is a comprehensive guide that ... to deal with KP (keratosis pilaris). This ...     Chapter 1: What Is Keratosis Pilaris? ,     Chapter ... Do I Know If I Have KP? , ...
(Date:7/12/2014)... July 12, 2014 The Chicken ... the past five years, buoyed by stable demand for ... management system. “Eggs are a relatively affordable staple for ... egg consumption generally grows in line with the size ... McKitterick. Furthermore, demand for new specialty egg products with ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3
... acoustic guitars to wounded guitar-playing service members as part of a ... in San Antonio, TX. , ... Pasadena, CA (PRWEB) ... will present over twenty new acoustic guitars to wounded guitar-playing service ...
... siRNA drug delivered systemically, FREMONT, Calif., June ... U.S. Food and Drug Administration (FDA) has,approved the ... drug candidate, DGFi, in kidney transplantation. The Company ... Delayed Graft,Function (DGF) in kidney transplant patients to ...
... at the Silicom Ventures Summit on June 29th-30th in Tel Aviv. ... ... Mind Ltd (SoM) was selected to present its concept and system for ... in Tel Aviv, Israel. The developed system, called SoM-ToUR, is based on ...
... condition a public health priority , , THURSDAY, June 26 ... kidney disease (CKD) is increasing, and the fact it raises ... public health priority, say Taiwanese researchers. , They analyzed data ... part in a standard medical screening program in 1994. The ...
... in the United States in recent years even though the ... by researchers at the Johns Hopkins Bloomberg School of Public ... percent among black men ages 25 to 44 and 12 ... is published in Online First edition of the Journal ...
... June 26 "The only way to flatten ... was the overriding,sentiment at last week,s I3 (insight, ... This statement made by keynote speaker,Wally Gomaa, president ... hospitals and employers must begin (or continue) working,together ...
Cached Medicine News:Health News:Freedom Celebration - Gibson Guitar to Provide Instruments for the Wounded 2Health News:Freedom Celebration - Gibson Guitar to Provide Instruments for the Wounded 3Health News:Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi 2Health News:Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi 3Health News:Step of Mind Ltd Will Present its Concept at the Silicom Ventures Summit 2Health News:Chronic Kidney Disease Growing Globally 2Health News:Researchers study hidden homicide trend 2Health News:Aegis Health Group Revealed Next Generation of Employer-Based Health-Improvement Strategies at Nashville Conference 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: